Pharma leaders look to AI while the industry argues it is under-credited

Pharmaceutical leaders are described as increasingly interested in AI to reinvent their businesses and use tools that could accelerate molecule research. The same assessment says the sector’s role as an inventor and creator of medicines is poorly understood, leaving companies unfairly villainized and in need of reclaiming the story.

GLP-1 drugs are cited as a major development in obesity treatment whose creators receive too little credit. The account also claims that bariatric surgeons have been applying for technology jobs and leaving medicine because GLP-1s have effectively eliminated bariatric surgery as a meaningful specialty in the country.